

## Elyxyb<sup>™</sup> (celecoxib) – New formulation approval

- On May 6, 2020, <u>Dr. Reddy's announced</u> the <u>FDA approval</u> of <u>Elyxyb (celecoxib)</u> oral solution, for the acute treatment of migraine with or without aura in adults.
  - Elyxyb is not indicated for the preventive treatment of migraine.
- Celecoxib is also available as generic oral <u>capsules</u>.
- Celecoxib is indicated for the management of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea.
- The efficacy of Elyxyb was demonstrated in two placebo-controlled studies in patients with acute migraine with or without aura. In study 1 and 2, 631 patients and 622 patients, respectively, were enrolled. Patients with migraines of moderate to severe pain intensity were evaluated for efficacy. The efficacy of Elyxyb was established by an effect on pain freedom at 2 hours post-dose and most bothersome symptom (MBS) freedom at 2 hours post-dose.
  - In study 1, 32.4% of the Elyxyb-treated patients vs. 25.3% of the placebo patients achieved pain freedom at 2 hours post-dose (p = 0.076) and 58.0% of the Elyxyb-treated patients vs. 44.4% of placebo patients reported MBS freedom at 2 hours post-dose (p = 0.003).
  - In study 2, 35.1% of the Elyxyb-treated patients vs. 21.0% of the placebo patients achieved pain freedom at 2 hours post-dose (p < 0.001) and 56.8% of the Elyxyb-treated patients vs. 43.9% of placebo patients reported MBS freedom at 2 hours post-dose (p = 0.006).</li>
- Elyxyb carries a boxed warning for the risk of serious cardiovascular and gastrointestinal events.
- Additional warnings and precautions for Elyxyb include hepatotoxicity; hypertension; heart failure
  and edema; renal toxicity and hyperkalemia; anaphylactic reactions; exacerbation of asthma related
  to aspirin sensitivity; serious skin reactions; medication overuse headache; premature closure of
  fetal ductus arteriosus; hematological toxicity; masking of inflammation and fever; laboratory
  monitoring; and disseminated intravascular coagulation.
- The most common adverse event (≥ 3% and > placebo) with Elyxyb use was dysgeusia.
- The recommended dose of Elyxyb is 120 mg taken orally, with or without food.
  - The maximum dosage in a 24-hour period is 120 mg. The safety and effectiveness of a second dose in a 24-hour period have not been established.
  - Elyxyb should be used for the fewest number of days per month, as needed.
- Dr. Reddy's launch plans for Elyxyb are pending. Elyxyb will be available as a 120 mg/4.8 mL (25 mg/mL) oral solution.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.